What is the dosage of Hadlima?

Hadlima is available in 5 dosages, including 50 mg/ml Auto-Injector 0.8 ml, 100 mg/ml Auto-Injector 0.4 ml, 50 mg/ml Prefilled Syringe 0.8 ml, 100 mg/ml Prefilled Syringe 0.4 ml and 50 mg/ml Injection 0.8 ml

What is Hadlima mechanism of action?

Hadlima mechanism of action is Tumor Necrosis Factor Receptor Blocking Activity

Hadlima Prescribing & Dosing Schedule

Q: What does Hadlima treat?

Hadlima treats Arthritis, Juvenile, Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Spondylitis, Ankylosing, Uveitis, Arthritis, Psoriatic and Hidradenitis Suppurativa

Q: What is Hadlima made of?

Hadlima contains adalimumab which is a Tumor Necrosis Factor Blocker

Q: How is Hadlima administered?

Hadlima is administered as a Injectable

Dosage & Administration

* Administer by subcutaneous injection

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis :

* Adults: 40 mg every other week.
* Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week.

Juvenile Idiopathic Arthritis :

Pediatric Weight 2 Years of Age and Older	Recommended Dosage
10 kg (22 lbs) to less than 15 kg (33 lbs)	10 mg every other week
15 kg (33 lbs) to less than 30 kg (66 lbs)	20 mg every other week
30 kg (66 lbs) and greater	40 mg every other week

Crohn's Disease :

* Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29.
* Pediatric Patients 6 Years of Age and Older:

Pediatric Weight	Recommended Dosage
Pediatric Weight	Days 1 and 15	Starting on Day 29
17 kg (37 lbs) to less than 40 kg (88 lbs)	Day 1: 80 mg Day 15: 40 mg	20 mg every other week
40 kg (88 lbs) and greater	Day 1: 160 mg (single dose or split over two consecutive days) Day 15: 80 mg	40 mg every other week

Ulcerative Colitis :

* Adults: 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15 and 40 mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57).

Plaque Psoriasis or Adult Uveitis ( 2.5):

* Adults: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.

Hidradenitis Suppurativa :

* Adults:
* Day 1: 160 mg (given in one day or split over two consecutive days)
* Day 15: 80 mg
* Day 29 and subsequent doses: 40 mg every week or 80 mg every other week

Get Your Patient on Hadlima

See your patient's specific prior authorization requirements including coverage restrictions and step therapies

Or select your Insurance from the list below:

Hadlima Prescribing Information

Report Adverse Event

Hadlima Financial Assistance Options

Copay savings program

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.